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Phosphoinositide 3-kinase d is upregulated in
lymphocytic leukemias. Because the p85-regulatory
subunit binds to any class IA subunit, it was assumed
there is a single universal p85-mediated regulatory
mechanism; however, we find isozyme-specific inhi-
bition by p85a. Using deuterium exchange mass
spectrometry (DXMS), we mapped regulatory inter-
actions of p110d with p85a. Both nSH2 and cSH2
domains of p85a contribute to full inhibition of
p110d, the nSH2 by contacting the helical domain
and the cSH2 via the C terminus of p110d. The
cSH2 inhibits p110b and p110d, but not p110a,
implying that p110a is uniquely poised for oncogenic
mutations. Binding RTK phosphopeptides disen-
gages the SH2 domains, resulting in exposure of
the catalytic subunit. We find that phosphopeptides
greatly increase the affinity of the heterodimer for
PIP2-containing membranes measured by FRET.
DXMS identified regions decreasing exposure at
membranes and also regions gaining exposure, indi-
cating loosening of interactions within the hetero-
dimer at membranes.
INTRODUCTION
Phosphoinositide 3-kinases (PI3Ks) are a family of enzymes that
catalyze the phosphorylation of the D3-hydroxyl of inositol phos-
pholipids. The lipid products of the reaction act as second
messengers and lead to downstream recruitment of phosphoi-
nositide binding proteins, which orchestrate many important
functions including cell proliferation and survival (Vanhaese-
broeck et al., 2010). PI3Kd is upregulated in some leukemias,
and a specific inhibitor of it (CAL-101) has entered clinical trials
for chronic lymphocytic leukemia (Lannutti et al., 2010). This iso-
form is abundant in leukocytes and has important roles in immu-
nity, inflammation and allergy. Like other class IA PI3Ks, it is an
obligate heterodimer of a p110 catalytic subunit (p110d) and a
p85-type regulatory subunit (p85a, p55a, p50a, p85b, or p55g)
and produces PtdIns(3,4,5)P3 lipids in vivo (Cantley, 2002; Geer-
ing et al., 2007). The p110a catalytic subunit is one of the most
frequently mutated oncogenes in human tumors, and PI3K inhi-Structure 19, 1127–bition is a major pharmacological target for drug discovery
(Samuels et al., 2004; Wong et al., 2010). The cancer-associated
p110a mutations upregulate the enzyme activity by different
mechanisms (Huang et al., 2008; Mandelker et al., 2009; Miled
et al., 2007; Wu et al., 2009; Zhao and Vogt, 2008). Because
any one of the regulatory subunits can interact tightly with any
of the class IA catalytic subunits, it is generally assumed that
all p110 subunits are inhibited in the same way. The importance
of understanding isoform-specific regulation of PI3Ks by p85 led
us to examine this assumption.
All of the p110 subunits consist of an adaptor-binding domain
(ABD), a Ras binding domain (RBD), a C2 domain, a helical
domain, and a kinase domain split into an N-lobe and a C-lobe
(Berndt et al., 2010; Huang et al., 2007; Walker et al., 1999).
The p85 subunits consist of an N-terminal SH3 domain, a break-
point cluster region (BCR) homology domain flanked by two
proline-rich regions, and two SH2 domains, nSH2 and cSH2,
separated by a coiled-coil region termed the inter-SH2 domain
(iSH2) (see Figure S1 available online). The ABD domain has
been shown to be necessary and sufficient to bind the regulatory
subunit, through interactions with the iSH2 domain (Dhand et al.,
1994). The regulatory subunits stabilize the catalytic subunit,
inhibit its basal activity, and activate PI3K in the presence of
phosphorylated tyrosine (pY) sequences in activated receptor
tyrosine kinases (RTKs) and adaptor proteins (Yu et al., 1998a,
1998b). The N-terminal SH2 domain (nSH2) in combination
with the iSH2 domain is the minimal construct of p85a required
to inhibit the activity of p110a (Yu et al., 1998a). This inhibition
can be relieved by RTK pY peptides. Constructs of the p110a
isoform with oncogenic mutations in the helical domain display
increased activity compared to the wild-type enzyme and have
no further increase in activity on RTK pY peptide binding (Carson
et al., 2008; Chaussade et al., 2009). However, regulation of the
p110d isoform by p85 and RTK pY peptides has not been
examined.
Understanding the dynamics between the catalytic and
regulatory subunits is central to understanding PI3K activity.
The structures of both the isolated nSH2 and cSH2 domains of
p85a with and without RTK pY peptides are known (Hoede-
maeker et al., 1999; Nolte et al., 1996), as well as the structure
of the niSH2 fragment bound to the full-length p110a (Mandelker
et al., 2009). The nSH2 domain binds the helical domain through
the surface required for pY peptide binding, and consequently
the presence of a pY peptide breaks the inhibitory contacts
between the catalytic and regulatory subunits (Mandelker
et al., 2009; Miled et al., 2007). Many of the cancer linked1137, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1127
Figure 1. Kinase Activity of p110d in the Presence of p85a Con-
structs and PDGFR pY
(A) p110d/p85a constructs tested for lipid kinase activity.
(B) Kinase activity of DABD-p110d compared with p110d /iSH2 p85a. Assays
measured 32P-PIP3 production in the presence of 0.5 nM enzyme, 100 mM
ATP, and 5% PIP2 lipid vesicles at a concentration of 1 mg/ml. The left panel
illustrates the autoradiogram of the filter (duplicate spots) and the right shows
the quantitation of the spots. Kinase assays were performed in duplicate and
repeated twice. The error bars show the standard deviation (SD).
(C) In vitro kinase assay results for various p110d and p85a constructs
are shown. Assays measured 32P-PIP3 production in the presence of 5 nM
enzyme, 100 mM ATP, and 5% PIP2 vesicles at a concentration of 1 mg/ml,
+/ 10 mM PDGFR pY. Kinase assays were performed in duplicate and
repeated twice.
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between the p110 catalytic and p85a subunits, one between
the iSH2 domain of p85 and the C2 domain of p110a, and one
between the nSH2 domain of p85 and the helical domain of
p110a (Huang et al., 2007; Miled et al., 2007; Wu et al., 2009).
However, no structural information exists for possible interac-
tions between the nSH2 and cSH2 domains with p110d.
The recently published structures of the free p110d catalytic
subunit (Berndt et al., 2010) contributed to developing isotype-
specific inhibitors, but they shed no light on how this isoform is
regulated by p85. Toward this end, we used deuterium exchange
mass spectrometry (DXMS) to explore the interactions between
the p110d and p85a. Due to recent advances in instrumentation
and analysis, DXMS has become a burgeoning and powerful
method for examining protein folding, protein-protein contacts,
protein-ligand binding, and conformational changes (Engen,1128 Structure 19, 1127–1137, August 10, 2011 ª2011 Elsevier Ltd A2009; Zhang et al., 2010). This technique has also been used
to study membrane associated enzymes interacting with phos-
pholipid vesicles (Burke et al., 2008a, 2008b; Hsu et al., 2009).
Using DXMS, we have localized p110d regions interacting with
the iSH2, nSH2 and cSH2 domains. Our lipid kinase assays
suggest that full inactivation of p110d requires a p85 construct
encompassing both SH2 domains (nicSH2). Binding of RTK pY
peptides to the SH2 domains exposed p110d regions protected
by the nSH2 and cSH2 domains to deuterium exchange, leading
to full activation of all constructs. DXMS results enabled us to
create a p85 point mutant that exposes the proposed cSH2
binding site on p110d, circumventing downregulation by the
cSH2 in vitro and increasing downstream signaling in cells.
Importantly, this same mutation also activates p110b, but not
p110a. Combining this cSH2 mutation with an oncogenic muta-
tion in the nSH2, which exposed the helical domain, results in
a p85 that fully activated p110d. Using FRET measurements,
we find that p110d/p85a complex binds very poorly to lipid vesi-
cles mimicking plasmamembrane composition, but pY peptides
greatly increased affinity of the complex for lipids, especially
when the vesicles contained PIP2 substrate. DXMS also enabled
us to identify for the first time specific regions in both the catalytic
and regulatory subunits that interact with lipidmembranes. Inter-
estingly, some regions of the ABD domain and iSH2 become
more exposed in the presence of membrane, indicating that
loosening of interactions within the complex accompanies
membrane binding.
RESULTS
The cSH2 of p85a Plays an Important Regulatory Role
for p110d
The regulation of p110a by p85 has been thoroughly studied (Yu
et al., 1998a, 1998b), and it has been assumed that the same
mechanism of regulation would govern all class IA enzymes,
including p110d. To examine this assumption, we first performed
lipid kinase assays to test which of the domains of p85a
contribute to inhibition of the basal activity of p110d. For the
assays we used vesicles containing 5% PIP2 and a defined
mixture of lipids mimicking natural membranes (20% PS/45%
PE/15% PC/10% cholesterol and 5% sphingomyelin) similar in
composition to previous studies examining plasma membrane
interactions (Corbin et al., 2007; Maier et al., 1999). We used
several truncated variants of the p85a regulatory subunit: iSH2
(residues 434–600), which has only the iSH2 domain; niSH2
(residues 322–600), which has both the nSH2 and iSH2 domains;
and nicSH2 (residues 322–724), which has the nSH2, iSH2, and
cSH2 domains (Figure 1A; Figure S1A). The regulatory subunits
were coexpressed and copurified with the full length p110d
catalytic subunit. To express the catalytic subunit free from a
regulatory subunit we used the DABD-p110d construct (DABD-
p110d, residues 106–1044), because the full-length p110d in
the absence of a regulatory subunit is insoluble (Berndt et al.,
2010). DABD-p110d had a 2.5-fold higher activity compared
to p110d+iSH2 (Figure 1B). Because both the ABD domain and
iSH2 domain are in contact with the kinase domain, either could
be inhibiting PI3K activity in the p110d+iSH2 complex. The
p110d+niSH2 complex was inhibited only 5-fold compared to
p110d+iSH2 (Figure 1C). However, the p110d+nicSH2 complexll rights reserved
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significantly less active than the p110d+niSH2 complex. The
inhibition of p110d by the cSH2 domain, in the context of the
nicSH2 construct, stands in sharp contrast with previous studies
on p110a, which showed that the minimal construct necessary
for full inhibition was the niSH2, and that the cSH2 does not
inhibit the basal activity of p110a, even though it was shown to
be necessary for full activation by a pY peptide (from IRS-1) in
the context of full length p85 (Rordorf-Nikolic et al., 1995; Yu
et al., 1998a).
We also tested if the presence of PDGFR bis-phosphorylated
pY peptide (residues 735–767, with pY740 and pY751, referred
to afterwards as PDGFR pY) can relieve inhibition imposed by
both the nSH2 and cSH2 domains. Indeed, we found that the
presence of PDGFR pY does fully relieve inhibition from both
the nSH2 and cSH2, which brings the enzyme activity for all
iSH2-containing complexes to a similar activated level, close
to the activity of the p110d+iSH2 (Figure 1C). The highest activa-
tion occurred with the nicSH2, which was activated 13-fold by
the PDGFR pY. The fold of activation is critically dependent on
the nature of the lipid substrate. However, the activation we
see is in line with studies on purified full length p110d/p85a
complex on PIP2-containing lipid vesicles showing a 20–40-
fold activation on addition of a pY peptide (Maier et al., 1999).
We carried out DXMS experiments to detect changes in protein
dynamics that might explain inhibition by both the nSH2 and
cSH2 domains of the regulatory subunit, and activation by
PDGFR pY binding.
Digestion of p110d and p85a Constructs/Global
Deuterium Exchange of p110d and p85a
The optimized peptide digestion map of the p110d (Figure S1B)
was composed of 116 individual peptic peptides, covering
83% of the sequence of the catalytic subunit, whereas the
map of the p85a nicSH2 regulatory subunit consisted of 53
peptides, covering 85% of the sequence of the regulatory
subunit. Four different enzyme complexes were studied by
deuterium exchange: p110d+p85a nicSH2 in the presence and
absence of PDGFR pY, p110d+p85a iSH2, and p110d alone
(DABD-p110d). No experiments were performed on the DABD-
p110d in the presence of p85a constructs due to previous
work showing no detectable binding of p85 by p110 without
the ABD domain (Dhand et al., 1994). All heterodimers had an
equal ratio of p110 and p85. The global exchange profile of
DABD-p110d is shown modeled onto the recently solved crystal
structure of the p110d catalytic subunit (Berndt et al., 2010) (Fig-
ure S2). The global exchange profile of the p85a nicSH2 was
modeled onto the structures of the isolated nSH2 (residues
323–432) and isolated cSH2 (residues 613–720) domains in
complexes with PDGFR-pY, and onto the isolated iSH2 (resi-
dues 431–600) (Hoedemaeker et al., 1999; Miled et al., 2007;
Nolte et al., 1996) (Figure S2).
Differences in Exchange of p85a in the Presence
of PDGFR pY
Differences in exchange rates for the p85a nicSH2 (bound to
p110d) in the presence and absence of a PDGFR pY were map-
ped onto the crystal structures of the nSH2, iSH2, and cSH2 of
p85a (Figure 2; Figure S3). It is important to note that many ofStructure 19, 1127–the deuterium exchange differences caused by p85a constructs
and PDGFR pY binding mapped on the crystal structures are on
the order of 1.0 Da within peptides that can incorporate >10
deuterons. Without sufficient overlapping peptides it is impos-
sible to precisely locate the position of these changes. Although
peptides with changes are colored in all figures, it is possible that
only one to two amides in these regions are affected. The nSH2
and cSH2 domains showed nearly global decreases in exchange
in the presence of PDGFR pY. This agrees with previous DXMS
work that shows global decreases in exchange for isolated SH2
domains bound to pY peptides (Engen et al., 1999). We were
most interested in looking for peptides that have increases in
exchange in the presence of PDGFR pY, as these might indicate
interfacial regions between p110d and p85a. Two p85a
peptides, 444–456 in the beginning of the iSH2 and 681–687 in
the cSH2, showed increases in exchange in the presence of
PDGFR pY. Peptide 444–456 also showed an increase in
exchange in the p110d+iSH2 complex in comparison with the
p110d+nicSH2. An increase in exchange was also seen with
peptides spanning the C-terminal end of the iSH2 (546–581) in
the absence of the nSH2 and cSH2 domains, suggesting that
the coiled-coil becomes more protected from exchange in the
presence of these two SH2 domains (Table S1B).
Peptide 681–687 in the cSH2 also showed an increase in
exchange (1.0 Da) in the presence of PDGFR pY. We hypothe-
sized that this region in the cSH2 might form a contact surface
for p110d, and that this interaction is broken in the presence of
PDGFR pY. No region on the nSH2 had an increase in exchange
in the presence of PDGFR pY. We would like to emphasize that
no change in exchange would be expected if the PDGFR pY
protects the same regions as are protected by p110d in the
absence of PDGFR pY. Previous crystallographic work on
p110a would predict that this is exactly the case for the nSH2
(Mandelker et al., 2009). We find that the cSH2 showed an
increase in exchange on PDGFR pY binding (region 681–687),
suggesting that the PDGFR pY binding surface of the cSH2
and the inhibitory contact surface with p110 do not completely
coincide, in contrast to the nSH2, where they do.
Differences in Exchange of p110d in the Presence
of p85a and PDGFR pY
To gain an insight into regions on p110d that are in contact with
the p85 subunit, we determined differences in exchange rates for
p110d in the presence of p85a constructs. Distinct regions in
p110d showed differences in exchange between the free cata-
lytic subunit (DABD-p110d) and p110d bound to the nicSH2 of
p85a (Figure 3A; Figure S4). By comparing the exchange differ-
ences between the p110d+iSH2 complex and the p110d+nicSH2
complex we were able to localize changes caused by binding to
the iSH2 domain, and changes that were caused by the nSH2
and cSH2 domains.
Differences in Exchange Caused by the iSH2
Four regions of p110d showed decreases in exchange between
the DABD-p110d and the p110d+iSH2 complex: 120–138 (in the
linker between the ABD and RBD), 327–337 and 453–468 (C2
domain), and 698–713 (in the N-lobe of the kinase domain)
(Figure 3A; Figure S4). The region 120–138 is located near the
interface with the ABD domain, and the change in deuteration
is most likely the consequence of the ABD deletion. Peptides1137, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1129
Figure 2. Changes in Deuteration Levels of the p85a nicSH2 Construct (Bound to p110d) in the Presence of 40 mM PDGFR pY
Peptides spanning p85a (A–M) that showed >0.5 Da changes in deuteration level in the presence and absence of PDGFR pY for the p110d+nicSH2 complex are
mapped onto the structures (2VIY for the iSH2, 2IUI for the nSH2, and 1H9O for the cSH2). The percent changemapped on the structure according to the legend is
the highest deuterium exchange difference change seen at any time point in the analysis. The structures of PDGFR pY bound to the nSH2 and cSH2 are colored
purple. Only peptides that showed >10% change for more than two time points are graphed and shown below the structures. Experiments were performed in
duplicate, and graphs are shown ± SD. All other peptides with changes >0.5 Da are shown in Figure S3. The graphs are labeled (*) for any time point with a >0.5 Da
change for the p110d+nicSH2 complex +/ PDGFR pY (see also Figure S3).
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Regulation of p110d Activity and Membrane Binding327–337, 453–468, and 698–713 of p110d are all located at or
near the crevice where the iSH2 domain binds in the p110a/
iSH2 structure (Huang et al., 2007). There was also a slight
decrease in exchange in peptide 920–935 spanning the
substrate-binding loop.
Helical Domain Changes Caused by nicSH2
and PDGFR pY
Several distinct peptides showed decreases in exchange in the
presence of the p110d+nicSH2 complex compared to the
p110d+iSH2complex.Oneof thesepeptides, 524–529, is located
in the helical domain and showed a decrease in exchange (>1.0
Da) (Figure 3A). This peptide contains E525, equivalent to E545
in p110a, which has been shown biochemically (Miled et al.,
2007) and structurally (Mandelker et al., 2009) to be important in
binding the nSH2. Experiments were also carried out with the
p110d+nicSH2complex in thepresenceofPDGFRpY (Figure3B).
The presence of PDGFR pY exposed this region to exchange to
the same extent as the free catalytic domain, suggesting that
PDGFR pY binding breaks the contacts between the nSH2 and
p110d. This is consistent with our lipid kinase assays showing
that the presence of PDGFR pY activates the p110d+niSH2
complex to the same level as the p110d+iSH2 complex, and
agrees with previous results for p110a (Miled et al., 2007).
Kinase Domain Changes Caused by nicSH2
and PDGFR pY
Peptides spanning the substrate-binding loop (920–935) and the
C-terminal end of the kinase domain (1010–1019, 1020–1022,1130 Structure 19, 1127–1137, August 10, 2011 ª2011 Elsevier Ltd Aand 1023–1033) also showed decreases in exchange in the
presence of the p110d+nicSH2 complex compared to the
p110d+iSH2 complex (Figure 3A). None of these peptides are
near the nSH2 contact site with the catalytic domain of p110a,
and we postulate that they may form a contact site for the
cSH2 in p110d. The largest decrease in exchange (2.0 Da) was
in the peptide from 1023–1033, but only at early time points,
with no changes in exchange after 100 s of on-exchange. These
changes were equally distributed through this region, because
peptides 1023-1027 and 1028-1033 showed decreases
(>0.7 Da) in exchange (Figure S4). This region spans the end of
helix ka11 and six residues following this helix, which are disor-
dered in the structure of p110d. This area forms the ‘‘elbow’’ in
p110g and class III Vps34 isoforms that connects the two
C-terminal helices ka11 and ka12 (Miller et al., 2010; Walker
et al., 1999). It has been recently shown that deletion of the
ka12 in Vps34 abolishes the lipid kinase activity (Miller et al.,
2010), so we tested an analogous deletion for p110d/p85a
nicSH2 (D1028-1044 in p110d). This deletion completely abol-
ishes p110d lipid kinase activity (Figure 1C). Therefore, the
DXMS experiments show that this region critical for catalysis
has one of the largest decreases in exposure caused by nicSH2.
Peptide 920–935 that spans the distal half of the substrate-
binding loop (residues 911–36 in p110d) showed a decrease in
exchange (>1.5 Da). The presence of PDGFR pY exposed this
peptide as well as the C-terminal peptides 1020–1022 and
1023–1033 in p110d+nicSH2 (Figure 3B) to the same extent asll rights reserved
Figure 3. Changes in Deuteration Levels of
p110d Catalytic Subunit in the Presence of
Both p85a and PDGFR pY
(A) Peptides spanning p110d (labeled A–I) that
showed >0.5 Da changes in deuteration level in the
presence and absence of the p85a nicSH2 are
mapped onto the DABD-p110d structure (2WXH)
according to the legend. Peptides that showed
>10% change for more than two time points are
graphed and shown below the figure. Experiments
were performed in duplicate, and graphs are
shown ± SD. All other peptides with changes
>0.5 Da are shown in Figure S4.
(B) Peptides spanning the p110d catalytic subunit
in the p110d+nicSH2complex that showed>0.5Da
changes in deuteration level in the presence and
absence of 40 mMPDGFR pY aremapped onto the
structure. The percent change mapped on the
structure according to the legend is the highest
deuterium exchange difference change seen at any
time point in the analysis. The area from1020–1022
is named a segment to denote that this data was
generated by subtraction of the deuterium level of
peptide 1001–1019 from peptide 1001–1022. The
graphs are labeled (*) for any time points with
a >0.5 Da change between the DABD-p110d and
p110d+nicSH2 constructs and (*) for any time point
with a >0.5 Da change for the p110d+nicSH2 +/
PDGFR pY (see also Figure S4).
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exchange for these regions correlated very well with our activity
results: addition of PDGFR pY to the p110d+nicSH2 complex
resulted in activity and deuteration levels similar to that of the
p110d+iSH2 complex. One peptide in the kinase domain,
939–958, only showed decreases in exchange (0.5 Da) when
comparing p110d+nicSH2 to DABD-p110d. This region is
located adjacent to the C-terminal helix and may form another
contact surface for the cSH2.
PDGFR pY Increases p110d/p85a Affinity
for Membrane Binding
To understand the PI3K activation by PDGFR pY binding we
examined the affinity of p110d for lipid membranes using
protein-lipid FRET as applied previously to examine Vps34 lipid
interactions (Miller et al., 2010). Two different types of lipid
vesicles were examined, one with 5% PIP2 present (20% PS/
10% Dansyl PS, 35% PE/15% PC/10% cholesterol, 5% sphin-
gomyelin, 5% PIP2), and one with 0% PIP2, where PIP2 was
replaced by PS. These experiments showed that the p110d/
p85a complex had very low lipid binding in the absence of
PDGFR pY. However, in the presence of PDGFR pY, the
p110d/p85a complex bound PIP2-containing vesicles with
much higher affinity (Figure 4). The DABD-p110d construct,
which is devoid of any inhibitory contacts imposed by p85 (as
well as lacking ABD), bound to PIP2-containing membranes
with high affinity, similarly to the PDGFR pY-activated p110d/
p85a (Figure 5). The presence of PDGFR pY had no effect on lipid
binding of the DABD-p110d. Binding to lipid vesicles containing
5% PIP2 was more efficient compared to vesicles lacking PIP2,
for both the free catalytic subunit and the PDGFR pY-activated
p110d/p85a construct. The PDGFR pY activation of p110d/Structure 19, 1127–p85a also caused a small increase in binding to lipid vesicles
lacking PIP2, showing that PIP2 substrate is not the only compo-
nent involved in PI3K binding to membranes.
Changes in Exchange Caused by Interaction
with Lipid Vesicles
PI3K must access its substrate at the lipid interface, and under-
standing changes in protein dynamics on binding the lipid
interface is important for understanding the mechanism of regu-
lation. Toward this end, we performed deuterium exchange
experiments at three time points (3, 30, and 300 s) with a PDGFR
pY-activated complex of p110d+nicSH2 in the presence and
absence of 5% PIP2-containing lipid vesicles. These experi-
ments were carried out in the absence of Mg2+ and ATP to
prevent enzyme activity. Several distinct regions in p110d
(698–715, 850–856, 908–919, 920–935, 939–958, 982–989, and
1024–1033) and p85a (414–420) had decreases in exchange in
the presence of lipid substrate (Figure 5; Figure S5). Regions
698–715 spanning the loop between ka1 and ka2 in the kinase
domain and 850–856 covering ka5 and the loop between ka4
and ka5 were both previously proposed to participate in
membrane binding (Huang et al., 2007; Mandelker et al., 2009;
Walker et al., 1999). Region 908–919 containing the beginning
of the substrate binding loop (encompassing the DFG motif)
also had a decrease in exchange in the presence of lipid vesicles.
Region 982–989 is adjacent to the substrate binding loop in the
structure. It contains part of ka9 and the loop connecting to
ka10. The p110a helix equivalent to p110d helix ka10 is known
to interact with the nSH2 domain (Mandelker et al., 2009). Region
1024–1033 at the C-terminal end of p110d is equivalent to the
C-terminal tail of class III PI3Ks that was shown to bind
membranes (Miller et al., 2010). Interestingly, regions 920–935,1137, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1131
Figure 4. Protein-Lipid FRET Measured from Intrinsic Tryptophanes
to the DANSYL Probe of the DANSYL-PS-Containing Liposomes of
the Free Catalytic Subunit and Full Length p110d/p85a Complex in
the Presence and Absence of PDGFR pY
(A) Lipid binding of the p110d/p85a complex with 0% and 5% PIP2 lipid
vesicles in the presence and absence of PDGFR pY.
(B) Lipid binding of the DABD-p110d construct with 0% and 5% PIP2 lipid
vesicles in the presence and absence of PDGFR pY. Experiments were
repeated in triplicate and graphs are shown ± SD.
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the nicSH2 and also all show an interaction with lipid vesicles,
suggesting that p85 greatly regulates the interaction of p110
with membranes.
Surprisingly, we find some regions that have an increase in
exchange in the presence of lipid vesicles. One is in p110d,
region 71–91, which is in the ABD domain, and the other two
are in the iSH2 domain of p85a (regions 467–476 and 556–
570). This indicates that the presence of lipid vesicles may
loosen the interaction between the iSH2 and the p110d. Experi-
ments were also performed on the full length p110d/p85a
complex in the presence of PDGFR pY and 10 mM Mg2+ with
and without 5 mM nonhydrolysable ATP analog, AMPPNP to
examine possible changes on nucleotide binding. No changes
were seen in the catalytic subunit on AMPPNP/Mg2+ binding
(data not shown). This is not surprising because peptides
spanning the ATP binding pocket (752–762, 886–900) experi-
ence <25% exchange even at 3000 s.
Engineering p85a Mutations that Activate p110d
DXMS identified the region from 681–687 in the cSH2 as part of
the interface with p110d. We hypothesized that the cSH2may be1132 Structure 19, 1127–1137, August 10, 2011 ª2011 Elsevier Ltd Aresponsible for the observed changes in exposure of the
C-terminal end of the p110d kinase domain when p110d is bound
to nicSH2 compared to free p110d. To test this hypothesis, we
mutated Tyr-685 in the p85a cSH2 to alanine. The p110d+
nicSH2 Y685A mutant complex showed higher basal activity
than the equivalent wild-type complex and the same basal
activity as the p110d+niSH2 complex. In the presence of PDGFR
pY, the mutant complex was activated to a similar level as the
niSH2 and nicSH2 complexes (Figure 1C). To examine if this
mutation was functionally important in the regulation of the full
length p110d/p85a complex, as well as to determine individual
effects of the nSH2 and cSH2, we purified full length complexes
containing the K379E nSH2mutation, the Y685A cSH2mutation,
and the double mutant K379E, Y685A. The engineered onco-
genic K379E mutation in nSH2 has been previously shown to
activate p110a both in vitro and in vivo (Miled et al., 2007; Sun
et al., 2010) by breaking the contact between the nSH2 and
the helical domain. Enzyme activity assays performed with 5%
PIP2 liposomes showed that the K379E or Y685A p85 mutations
activate the enzyme 10-fold and 5-fold, respectively (Figure 6A),
and that the presence of both mutations fully activated the
enzyme, and made it insensitive to further PDGFR pY activation.
Deuterium exchange experiments were then carried out on the
K379E, Y685A, and double mutant complexes. Both of these
mutations maintained the ability to bind PDGFR pY as shown
by similar decreases in exchange in peptide 414–420 of the
nSH2 and 704–710 of the cSH2 in the presence of PDGFR pY
(Figure S6). The presence of the nSH2mutation (K379E) exposed
the p110d helical domain peptide 524–529 to a similar level as
when in the presence of PDGFR pY, whereas the Y685A muta-
tion exposed the elbow peptide 1023–1033 of the p110d kinase
domain (Figure 6C), as well as the substrate binding loop peptide
920–935 (Figure S6). This C-terminal elbow showed a 1.0 Da
increase in exchange at 3 s of on-exchange in the Y685A mutant
complex compared with wild-type, and showed a further 1.0 Da
increase in the presence of PDGFR pY (Figure 6C). The peptide
681–687 in p85a that showed an increase in exchange in the
presence of PDGFR pY in wild-type p85a, showed a decrease
in exchange for the Y685A construct due to rigidification of the
entire cSH2 domain in the presence of PDGFR pY (Figure S6).
This is further evidence that this p85 region represents a key
contact site with the catalytic subunit, and that the presence of
the Y685A mutation in the cSH2 does not disrupt PDGFR pY
binding. The peptide 444–456 in the iSH2 domain of p85a
showed a 1.0 Da increase in exchange at 1000 s in the double
mutant complex compared to wild-type and was further
exposed by the addition of PDGFR pY (Figure S6). To test the
possible effect of mutations in this region on enzyme activity
we expressed the full length complex of p110d/p85a with the
previously determined p85a oncogenic mutation L449S (Jaiswal
et al., 2009) and found that this mutation increased basal activity
2-fold and showed activation by PDGFR pY that was similar to
the wild-type (Figure 6B).
In addition, cellular assays looking at PI3K downstream sig-
naling showed a 2-fold increase in Akt phosphorylation for cells
transiently cotransfected with the p110d+p85a Y685A com-
pared to the cells cotransfected with p110d+p85a (Figure 7A).
A p110d +p85a N564D complex, carrying a somatic mutation
in the iSH2 previously demonstrated to potently activate PI3Kll rights reserved
Figure 5. Changes in Deuteration Levels of p110d and p85a in the Presence of 5% PIP2 Vesicles at 1 mg/ml
Amodel for the iSH2 domain of p85a and ABD domain of the p110dwas generated by combining theDABD-p110d structure (2WXH) with the structure of p110a in
complex with niSH2 (3HIZ) (Mandelker et al., 2009). The C-terminal helix of the kinase domain that is disordered in p110d is modeled (region H) from the structure
of p110g (1E7U) (Walker et al., 1999). Peptides spanning p110d and p85a (labeled A–K) that showed >0.5 Da changes in deuteration level in the presence of
vesicles are mapped onto the model. The percent changemapped on the structure according to the legend is the highest deuterium exchange difference change
seen at any time point in the analysis. Peptides that showed a >10% change at any time point are graphed and shown below the figure. Experiments were
performed in duplicate, and graphs are shown ± SD. All other peptides with changes >0.5 Da are shown in Figure S5. The graphs are labeled (*) for any time points
with a >0.5 Da change between p110d+nicSH2 + pY in the presence of lipids (see also Figure S5).
Structure
Regulation of p110d Activity and Membrane Bindingsignaling, resulting in oncogenesis (Jaiswal et al., 2009), showed
a similar increase in Akt phosphorylation (Figure 7A).
To determine if there were any p110 isoform specific differ-
ences in regulation by cSH2, we purified full-length complexes
of human p110a, p110b, and p110d with and without the Y685A
mutation in p85a. Enzyme activity assays performed with 5%
PIP2 liposomes showed that both p110d and p110b were
activated by the mutation, whereas p110a was not (Figure 7B).
DISCUSSION
Understanding the regulation of different isoforms of the class IA
PI3Ks is an important goal due to their prominent and isotype-
specific roles in human diseases including cancer, diabetes,
inflammation, thrombosis, allergy, and cardiac disease. In the
absence of activators such as phosphorylated RTKs, the basal
activity of p110d is very low, kept tightly suppressed by p85.
Understanding the dynamic interactions between the catalytic
and regulatory subunits is important in defining the mechanism
of PI3K regulation. The crystal structure of p110a with the
niSH2 construct of p85a shows contacts formed between the
two subunits (Mandelker et al., 2009), but it does not explainStructure 19, 1127–how these contacts translate into inhibition of the enzyme.
DXMS for p110d/p85a has allowed us to interrogate how con-
tacts between the regulatory and catalytic subunits cause
dynamic changes throughout the enzyme.
The presence of the iSH2 caused decreases in exchange all
along the crevice of the p110d where the iSH2 is predicted to
bind (based on the crystal structures of p110a and p110b
complexes) (Mandelker et al., 2009; Zhang et al., 2011). One of
the regions in the C2 domain with decreased exchange in the
presence of the iSH2 contains Asn334, equivalent to Asn345 in
p110a. This is consistent with the published data showing that
the interaction between this residue and Asp560/Asn564 in the
iSH2 participates in the inhibition of p110a (Wu et al., 2009).
The presence of the nicSH2 construct caused decreases in
exchange at a region in the helical domain, showing that the
interaction with the nSH2 previously demonstrated for p110a is
conserved in p110d (Mandelker et al., 2009). Decreases were
also seen at the C-terminal elbow following helix ka11, which
we predict forms an interface with the cSH2. We showed that
the p110d C-terminal region has a critical role in catalysis,
because a deletion construct missing the last 17 residues
(from 1028 to 1044) had undetectable lipid kinase activity toward1137, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1133
Figure 6. Effect of the p85a K379E and Y685A
Mutations on Lipid Kinase Activity and Deuterium
Exchange in Vitro with a Model of p110d/p85a
Regulatory Interaction
(A) PI3K activity of p110d, with full length p85a constructs
containing nSH2 (K379E) and cSH2 (Y685A) mutations in
the presence and absence of PDGFR pY. Assays mea-
sured 32P-PIP3 production in the presence of 10 nM
enzyme, 100 mM ATP and 5% PIP2 lipid vesicles at a
concentration of 1 mg/ml. PDGFR pY was 10 mM.
(B) PI3K activity of p110d, with full-length p85a containing
the cancer-linked L449S iSH2 mutation in the presence
and absence of PDGFR pY. All lipid kinase activity assays
were performed in triplicate and graphs are shown ± SD.
(C) The deuteration level at 1000 s of on-exchange
for a helical domain peptide (524–529), and at 3 s of on
exchange for a C-terminal peptide (1023–1033) was
plotted for eight conditions as indicated on the legend.
Experiments were performed in duplicate, and graphs are
shown ± SD.
(D) A structural model for the interaction of p110d with the
nSH2, iSH2, and cSH2 domains of p85a was generated
using the crystal structure of the free p110d catalytic
subunit (2WXH), with the nSH2 from the p110a/p85a
structure (3HHM), the iSH2 (2VIY), and the cSH2 from the
recent p110b/p85b structure (2Y3A). Regions with
changes on phosphopeptide binding are colored in red
and labeled on the model (see also Figure S6).
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Regulation of p110d Activity and Membrane BindingPIP2 containing liposomes. The C-terminal end of the substrate-
binding (activation) loop also showed decreases in exchange in
the presence of various p85a constructs, and it is interesting
that themore protected this region was, the lower the lipid kinase
activity. This region would not be predicted to be in contact with
the cSH2, and is located directly underneath helix ka11 and mayFigure 7. Effect of the p85a Y685A Mutation on Lipid Kinase Activity In
Regulatory Interaction
(A) Y685Amutation in the cSH2 of p85a (Y685A) increases Akt phosphorylation (Se
mean ± SEM (n = 3) of phosphorylated Akt (pAkt) to Akt ratios normalized to wild
(B) PI3K activity of p110d, p110a, and p110b in the presence of full length p85a (W
32P-PIP3 production in the presence of 10 nM enzyme, 100 mMATP and 5%PIP2 l
were performed in duplicate and repeated three times. Shown is a representativ
(C) Amodel for the regulation of p110d and p110a basal activity by the nicSH2 dom
domains prevents lipid binding, and binding of PDGFR pY exposes lipid interact
1134 Structure 19, 1127–1137, August 10, 2011 ª2011 Elsevier Ltd Arepresent an allosteric change on rigidification of helix ka11. The
same regions in p110d that had decreases in exchange with the
nSH2 and cSH2 showed an increase in the presence of PDGFR
pY, restoring the same level of exchange observed with only the
iSH2. These observations indicate that breaking these contacts
disinhibits the enzyme.Vitro and PI3K Signaling in Cell Culture with a Model of p110d/p85a
r473) in HEK cells overexpressing p110d+p85a heterodimers. Bar graphs show
-type p110d+p85a (WT).
T and Y685A) in the presence and absence of PDGFR pY. Assays measured
ipid vesicles at a concentration of 1mg/ml. PDGFR pYwas 10 mM. PI3K assays
e experiment with graphs shown ± SD.
ains of p85a and activation by PDGFR pY. The presence of the nSH2 and cSH2
ing regions and increases membrane affinity.
ll rights reserved
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Regulation of p110d Activity and Membrane BindingWe find that p110d/p85a disinhibition correlates with
increased enzyme affinity for membrane vesicles: the p110d/
p85a complex binds membranes very poorly and the addition
of PDGFR pY greatly increases the affinity of the p110d/p85a
for PIP2-containing membranes and to a lesser extent also to
membranes lacking PIP2. The binding of the PDGFR pY-acti-
vated p110d/p85a to membranes is similar to the binding of
the free catalytic subunit,DABD-p110d that is devoid completely
of p85 inhibitory contacts. This surprising result that the free
catalytic subunit can bind lipid as effectively as the activated
p110d/p85a complex contrasts with the hypothesized role of
the iSH2 domain in lipid binding (Huang et al., 2007). Regions
exposed in the kinase domain on PDGFR pY binding had
decreases in exchange in the presence of lipid substrate,
revealing that PDGFR pY binding is critical in exposing regions
of the protein that interact with the lipidmembrane.We expected
to see changes in the C2 domain due to lipid interaction (Denley
et al., 2008), however, we see no significant changes, but no
peptic peptides covering the CBR3 region of the C2 domain
were identified and analyzed.
In order to generate a regulatory subunit that would selectively
disrupt the contact between the cSH2 and catalytic domains, we
made a Y685A p85a mutant based on our finding that the
peptide containing this residue becomes exposed on PDGFR
pY binding. This mutation caused an increase in basal activity
of p110d, increased downstream signaling in cells and led to
exposure of the C-terminal end of the C-lobe and substrate-
binding loop, while not affecting exchange at the helical domain
nor the PDGFR pYbinding site. This engineeredmutation in p85a
also activated recombinant p110b but did not activate p110a,
revealing isoform specific aspects of regulation. This mutation
has been recently found to activate p110b in a complex with
p85b as well, and the crystal structure of p110b with the icSH2
construct of p85b shows that this Tyr residue is located at the
center of the interface between the catalytic and regulatory
subunit (Zhang et al., 2011). The presence of a previously identi-
fied engineered oncogenic nSH2 mutation (K379E) alone
increased the lipid kinase activity and the presence of the double
mutant (K379E, Y685A) in p85a fully activated the enzyme aswell
as exposing similar regions to exchange as in the PDGFR pY
activated complex (Figure 6D). These p85 point mutations
allowed us to isolate specific effects of the nSH2 and cSH2
domains on the dynamics of the p110d subunit.
Based on our results, and using the previously solved struc-
tures of p110a with the niSH2 construct of p85a (Mandelker
et al., 2009) and p110b with the icSH2 construct of p85b (Zhang
et al., 2011) we have constructed a model for the regulation of
p110d by the nicSH2 domains of p85a (Figure 6D). We propose
that both the nSH2 and cSH2 play important roles in inhibiting
the kinase activity of p110d, in contrast to p110a, which is
inhibited only by the nSH2 (Figure 7C). The nSH2 and cSH2
domains prevent binding of p110d/p85a to membranes. Binding
of PDGFR pY breaks inhibitory contacts formed by the nSH2
and cSH2 with p110d and increases affinity for membrane
vesicles.
Several oncogenic mutations in p85a have been recently
identified and analyzed (Jaiswal et al., 2009; Sun et al., 2010;
Wu et al., 2009). Two of them map to regions in the p85 where
we see increases in exchange in the presence of PDGFR pYStructure 19, 1127–(L449S in the iSH2 and A682V in the cSH2). We have shown
that the L449S mutation activates the basal enzyme activity.
The presence of the A682V mutation, which is located in the
proposed interface of the catalytic subunit with the cSH2, may
contribute to relieving the inhibitory cSH2 contact. Many of the
iSH2 mutations are located in or closely adjacent to regions
where we see an increase in exchange in the presence of lipid
vesicles (D464H, D560Y, N564K/D, and L570P). Because we
show that interaction with lipid vesicles causes a loosening
between the iSH2 and p110d, these mutations may mimic this
membrane-mediated loosening and activate by disrupting the
interaction between iSH2 and p110, as previously proposed
(Wu et al., 2009).
This is the first study to examine the dynamic interactions
of heterodimeric complexes containing the full-length class IA
catalytic subunit with its regulatory subunit, and show how the
addition of PDGFR pY as well as lipid vesicles affects these inter-
actions. Based on these, we have identified a novel isoform-
specific regulatory function for the cSH2 of p85a with p110d.
For the first time, we have shown that RTK pY peptide binding
directly increases membrane binding of the class IA hetero-
dimer. We mapped multiple regions of an activated PI3K that
interact with membranes and provide experimental evidence
for the dynamic interaction with lipids. The gain in exposure in
some regions in the presence of membranes indicates that
loosening of interactions between the p110d/p85a complex ac-
companies catalysis on membranes. Our DXMS results provide
a framework for designing further structural and biochemical
approaches to understand regulation of the PI3K and PI3K like
enzyme families.
EXPERIMENTAL PROCEDURES
Protein Expression and Kinase Assays
All protein constructs were expressed in Sf9 cells as described for the DABD-
p110d (Berndt et al., 2010). Full details are described in the Supplemental
Experimental Procedures.
Lipid Kinase Assays
The lipid kinase activity was determined using a modified membrane capture
assay measuring production of 32P-labeled PIP3 (Knight et al., 2007). Lipid
vesicles were used at a final concentration of 1 mg/ml and were composed
of 5% brain PIP2, 20% brain PS, 45% brain PE, 15% brain PC, 10% choles-
terol, and 5% sphingomyelin (Avanti Polar Lipids). Vesicle preparation is
described in Supplemental Experimental Procedures. The lipid solution was
mixed with each protein construct, with a final buffer containing 3 mM
MgCl2, 1 mM EGTA, 20 mM Tris pH-7.5, 50 mM NaCl, and 50 mM KCl. Reac-
tions were started by adding 100 mM ATP (final concentration) containing
0.1 mCi per mL of [g32P]-ATP in a total volume of 15 mL. This reaction was
carried out for sixty minutes, and was stopped by mixing 3 ml of the reaction
mixture with 3 ml of 20 mM EDTA. Three microliters of this mixture was then
spotted on a nitrocellulose membrane. The membrane was washed six times
with a 1 M NaCl/1% phosphoric acid solution. After all washes the membrane
was dried for one hour, followed by a 5–20min exposure to a phosphor screen
(Molecular Dynamics). The spot intensity on the phosphor screen was imaged
using a Typhoon phosphoimager (GE Healthcare). The intensity was quanti-
tated using ImageQuant (GE Healthcare).
Deuterium Exchange Measurements
Stock solutions of protein (30 pmol/ml) were prepared in 20 mM Tris pH-7.2,
50 mM ammonium sulfate, 1% ethylene glycol, and 5 mM DTT following the
procedure in the Supplemental Experimental Procedures. Measurements in
the presence of PDGFR pY were carried out by a 5-fold dilution of a 1 mM1137, August 10, 2011 ª2011 Elsevier Ltd All rights reserved 1135
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Regulation of p110d Activity and Membrane BindingPDGFR pY (mouse PDGFR residues 735–767, peptide sequence ESDGG(pY)
MDMSKDESID(pY)VPMLDMKGDIKYADIE) stock in 10 mM HEPES pH-7.2,
2% DMSO giving a final concentration of 200 mM PDGFR pY before addition
of deuterium. Exchange reactions were initiated by the addition of 4 ml of
protein stock to 1 ml of either PDGFR pY solution or blank and allowed to equil-
ibrate for 10 min followed by the addition of 25 ml of a 98% D2O solution con-
taining 10 mM HEPES pD-7.2, 50 mM NaCl, and 2 mM DTT, giving a final
concentration of 82% D2O. Deuterium exchange reactions were allowed to
carry on for five time points, 3, 10, 100, 1000, and 3000 s of on-exchange at
23C, before addition of quench buffer. For 3 s of on-exchange, an experiment
was also performed at 0C to examine exchange rates of extremely rapidly
exchanging amide hydrogens. On-exchange was stopped by addition of
40 ml of quench buffer containing 1.2% formic acid and 1.66 M Guanidine-
HCl, which lowered the pH to 2.6. Samples were then immediately frozen in
liquid nitrogen until mass analysis. Every time point and conditionwas a unique
experiment, and every DXMS experiment was repeated in duplicate.
For DXMS studies on the K379E, Y685A, and double mutants, on-exchange
experiments were carried out on the full length complexes of p110d and p85a
at two time points (3 and 1000 s) that between them covered all time points
with differences in exchange on nicSH2 binding.
For lipid binding experiments, lipid vesicles were prepared at 5 mg/ml as
described in Lipid Kinase Assays and were diluted 5-fold with a 98% D2O
solution containing 10 mM HEPES pD-7.2, 50 mM NaCl, and 2 mM DTT.
Deuterium exchange reactions were started by mixing 5 ml of a protein stock
solution (15 pmol/ml) with 25 ml of deuterated lipid buffer (25 mg phospholipid)
giving a final solution of 65% D2O. Half as much protein was used in lipid
binding experiments to maximize the ratio of lipid to protein in the sample.
Higher concentrations of protein or lipid in the sample led to sample aggrega-
tion. For this reason there was no chance to preincubate the protein solution
with lipid vesicles before addition of D2O due to aggregation of protein when
combined with high levels of lipid vesicles.
For AMPPNP binding experiments, protein was incubated with 10 mMMg2+
and +/ 5 mM AMPPNP for 15 min and then 5 ml of the protein/nucleotide
solution was diluted with 25 ml of deuterated buffer. All other steps remained
the same.
Full experimental procedures are described in the Supplemental Experi-
mental Procedures.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
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